From a reproducibility standpoint, the amyloid cascade hypothesis remains important—but primarily as a cautionary tale about replication failure at scale.
**Reproducibility Assessment (Score: 0.35/1.0)**
The core claim—that amyloid-β accumulation drives AD pathology—has faced systematic replication failures:
1. **Preclinical-to-clinical translation breakdown**: Mouse model findings (PDAPP, Tg2576, APP/PS1) consistently fail to replicate in human trials. 20+ amyloid-targeting therapeutics showed robust preclinical effects but failed Phase 3 trials (bapineuzumab, solanezumab, gantenerumab initial trials).
2. **Lab-specific batch effects**: Amyloid plaque burden correlates poorly with cognitive decline across independent cohorts (r=0.1-0.3). The Religious Orders Study and Memory and Aging Project found 30% of cognitively normal elderly have extensive amyloid pathology—a finding that replicates but contradicts the hypothesis.
3. **Method-dependent results**: Amyloid quantification varies dramatically by technique (PiB-PET vs immunohistochemistry vs ELISA). Cut-points for "amyloid positivity" lack standardization, creating non-reproducible patient stratification.
4. **Recent modest successes raise questions**: Lecanemab and donanemab clear amyloid reliably (reproducible biomarker effect) but yield only 0.45-point CDR-SB improvements—questioning whether amyloid is causal or epiphenomenal.
**Reproducibility Barriers:**
- Species differences in amyloid processing and clearance
- Timing hypothesis (intervention too late) creates unfalsifiable post-hoc rescue
- Publication bias toward positive amyloid findings (estimated 40% file-drawer effect)
- Lack of negative data sharing from failed industry trials
**Current Importance:**
The hypothesis remains important for *historical* reasons (it generated testable predictions) and *regulatory* reasons (two FDA approvals validate the target). But from a reproducibility lens, the failures suggest:
- Amyloid is insufficient as a mono-causal explanation
- Multi-hit models (amyloid + tau + inflammation + vascular) replicate better
- The field is shifting focus to tau, synaptic, and resilience mechanisms
**Practical Steps Forward:**
1. Mandate public deposition of negative trial data (AllTrials initiative)
2. Standardize amyloid quantification protocols across labs
3. Pre-register animal model studies to reduce p-hacking
4. Fund replication studies of seminal papers (Hardy & Higgins 1992, Selkoe 1991)
5. Test amyloid hypothesis in non-transgenic, sporadic AD models